All NewsFDA BriefsOncology IconsSpecial ReportsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPrecision MedicineSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2 Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE
Advertisement

Update on HER2-Targeted Therapy in Early Breast Cancer

home / investigator-perspectives / update-on-her2-targeted-therapy-in-early-breast-cancer

Sara M. Tolaney, MD, MPH, discusses newer approaches to managing early stages of HER2+ breast cancer in both the neoadjuvant and adjuvant spaces.

HER2 Assessment in Breast Cancer

EP. 1: HER2 Assessment in Breast Cancer

Sara M. Tolaney, MD, MPH
May 11th 2020

Watch

Neoadjuvant Approaches for Early-Stage HER2+ Breast Cancers

EP. 2: Neoadjuvant Approaches for Early-Stage HER2+ Breast Cancers

Sara M. Tolaney, MD, MPH
May 11th 2020

Watch

HER2 Heterogeneity and Neoadjuvant Therapy in Breast Cancer

EP. 3: HER2 Heterogeneity and Neoadjuvant Therapy in Breast Cancer

Sara M. Tolaney, MD, MPH
May 11th 2020

Watch

Neoadjuvant T-DM1 in Early-Stage HER2+ Breast Cancer

EP. 4: Neoadjuvant T-DM1 in Early-Stage HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH
May 11th 2020

Watch

The APHINITY Trial in Early-Stage HER2+ Breast Cancer

EP. 5: The APHINITY Trial in Early-Stage HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH
May 11th 2020

Watch

Adjuvant T-DM1 Therapy for Early-Stage HER2+ Breast Cancer

EP. 6: Adjuvant T-DM1 Therapy for Early-Stage HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH
May 11th 2020

Watch

The ExteNET Study & Management of HER2+ Breast Cancer

EP. 7: The ExteNET Study & Management of HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH
May 11th 2020

Watch

Novel Approaches for Stage I HER2+ Breast Cancer

EP. 8: Novel Approaches for Stage I HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH
May 11th 2020

Watch

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2024 MJH Life Sciences

All rights reserved.